Methyl N^δ-Phthaloyl-L-ornithinate Hydrochloride | 118537-45-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl N^δ-Phthaloyl-L-ornithinate Hydrochloride
• 英文别名: methyl 2-L-amino-5-phthalimididopentanoate hydrochloride；methyl 2-L-amino-5-phthalimidopentanoate；2-L-amino-5-phthalimidopentanoate；(S)-Methyl 2-amino-5-(1,3-dioxoisoindolin-2-yl)pentanoate hydrochloride；methyl (2S)-2-amino-5-(1,3-dioxoisoindol-2-yl)pentanoate;hydrochloride
• CAS: 118537-45-4
• 化学式: C₁₄H₁₆N₂O₄*ClH
• 分子量: 312.753
• InChiKey: GLFBFRCSQVTOCR-MERQFXBCSA-N

物化性质

• 熔点：
  192-193 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.98
• 重原子数：
  21.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  89.7
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  Methyl N^δ-Phthaloyl-L-ornithinate Hydrochloride 在 platinum(IV) oxide 氢气 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 27.25h， 生成 methyl N^α-(4-aminobenzoyl)-N^δ-phthaloyl-L-ornithinate
  参考文献：
  名称：

  氨基蝶呤和3'，5-二氯氨基蝶呤的Nω-半邻苯二甲酰基-α，ω-二氨基链烷酸类似物的合成和生物活性。

  摘要：

  Nα-（4-氨基-4-脱氧蝶酰基）-Nδ-（半邻苯二甲酰基）-L-鸟氨酸（PT523）的类似物，在对氨基苯甲酰基部分具有3'，5'-二氯取代，或具有一个或多个或多个合成了氨基酸部分中的CH2基团，并将其作为二氢叶酸还原酶（DHFR）活性和细胞生长的抑制剂进行了测试。用L-2,4-二氨基丁酸或L-赖氨酸替代PT523中的L-鸟氨酸不会降低与人重组DHFR的结合力，但会导致针对SCC25人和SCC VII鼠鳞状细胞癌以及针对MCF-7的活性丧失人类乳腺癌的文化。PT523的效力比甲氨蝶呤（MTX），氨基蝶呤（AMT）或曲美脲（TMQ）强几倍。3'，5'-二氯取代不会降低DHFR结合或细胞毒性。从2到PT523的新合成路线 研究了4-二氨基-6-（羟甲基）蝶啶和甲基Nα-（4-氨基苯甲酰基）-N-邻苯二甲酰基-L-鸟氨酸盐，但没有发现其优于前述方法。在有关PT523和MTX竞争性抑制（6R）-5

  DOI：

  10.1021/jm00040a008
• 作为产物：
  描述：

  N^δ-phthaloyl-L-ornithine 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成 Methyl N^δ-Phthaloyl-L-ornithinate Hydrochloride
  参考文献：
  名称：

  (6R,6S)-5,8,10-Trideaza-5,6,7,8-tetrahydrofolate and (6R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydropteroyl-L-ornithine as potential antifolates and antitumor agents. 35

  摘要：

  (6R,6S)-5,8,10-三去氮-5,6,7,8-四氢蝶酰酸通过多步反应由4,4-(环氧乙烷氧基)-环己酮和[4-(叔丁基氧基羰基)苄基]三苯基𬭸溴化物合成，并进一步转化为(6R,6S)-5,8,10-三去氮-5,6,7,8-四氢蝶酰-L-谷氨酸和(6R,6S)-5,8,10-三去氮-5,6,7,8-四氢蝶酰-L-精氨酸。化合物1被发现是部分纯化的鼠肝叶酸多谷氨酸合成酶（FPGS）的良好底物，其米氏常数（Km = 15 μM）与报道的还原型叶酸底物（6S）-5,6,7,8-四氢蝶酰-L-谷氨酸以及(6R,6S)-5,10-二去氮-5,6,7,8-四氢蝶酰-L-谷氨酸（DDATHF）的值相当。然而，与具有强细胞毒性的DDATHF形成鲜明对比的是，化合物1在高达100 μM的浓度下未能抑制肿瘤细胞的生长。这些结果表明，DDATHF中位于8号位的NH对于细胞毒性活性至关重要，但并非多谷氨酸化的必要条件。与1作为FPGS的良好底物类似，精氨酸类似物2证明是迄今为止发现的对该酶的较强竞争性抑制剂之一，其Ki值为10 μM。尽管2与5,6,7,8-四氢蝶酰-L-精氨酸（H4PteOrn）相比结合亲和力较低，但在N5、N8和N10位被碳取代的情况下，仍观察到显著的FPGS抑制作用。这表明，FPGS对环B和桥区的生物等价替代表现出一定的耐受性。化合物1和2在高达100 μM的浓度下均未显示出抑制细胞生长的活性。作为潜在前药的化合物2的Nδ半邻苯二甲酰衍生物也未表现出活性。

  DOI：

  10.1021/jm00123a037

文献信息

• Non-glutamate Type Pyrrolo[2,3-d]pyrimidine Antifolates. III. Synthesis and Biological Properties of N.OMEGA.-Masked Ornithine Analogs.
  作者：Fumio ITOH、Yoshio YOSHIOKA、Koichi YUKISHIGE、Sei YOSHIDA、Koichiro OOTSU、Hiroshi AKIMOTO

  DOI：10.1248/cpb.48.1270

  日期：——

  The glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-g lutamic acid (1b, TNP-351) and the related compound (1a), was replaced with various N(omega)-acyl-, sulfonyl-, carbamoyl- and aryl-2,omega-diaminoalkanoic acids, and the inhibitory effects of the resulting products (9, 11, 14, 18, 21, 23, 25, 30, 36) on dihydrofolate reductase (DHFR), the growth of

  N- [4- [3-（2,4-二氨基-7H-吡咯并[2,3-d]嘧啶-5-基）丙基]苯甲酰基] -Lg谷氨酸的谷氨酸部分（1b，TNP-351 ）和相关化合物（1a）替换为各种N（ω）-酰基-，磺酰基-，氨基甲酰基-和芳基-2，ω-二氨基链烷酸，以及所得产物的抑制作用（9、11、14分别在二氢叶酸还原酶（DHFR）上检测了18、21、23、25、30、36），小鼠纤维肉瘤Meth A细胞和耐甲氨蝶呤的人CCRF-CEM细胞的生长。通过偶合吡咯并[2,3-d]嘧啶羧酸（7a，b）和N（ω）-邻苯二甲酰基2，ω-二氨基链烷酸甲酯（6a-）有效地合成了被半邻苯二甲酰基化的化合物（9a-f） c）和随后的水解。其他N（ω）-酰基和磺酰基-鸟氨酸类似物（21，23，25）通过酰化衍生自叔丁氧基羰基鸟氨酸类似物（17a，b）的游离氨基中间体（19a，b）而合成。游离鸟氨酸类似物（18）不能强烈抑制Meth
• Synthesis and In Vitro Antitumor Activity of New Deaza Analogues of the Nonpolyglutamatable Antifolate <i>N</i>^α-(4-Amino-4-deoxypteroyl)-<i>N</i>^δ-hemiphthaloyl-<scp>l</scp>-ornithine (PT523)
  作者：Chitra M. Vaidya、Joel E. Wright、Andre Rosowsky

  DOI：10.1021/jm010518t

  日期：2002.4.1

  of CCRF-CEM human leukemic lymphoblasts, the IC(50) of 2 and 6 was 0.69 +/- 0.044 nM and 1.3 +/- 0.35 nM, respectively, as compared with previously reported values 4.4 +/- 0.10 nM for aminopterin (AMT) and 1.5 +/- 0.39 nM for PT523. In a spectrophotometric assay of dihydrofolate reductase (DHFR) inhibition using dihydrofolate and NADPH as the cosubstrates, the previously unreported compounds 2 and the

  公开了合成Nα-[4- [2-（2，4-二氨基喹唑啉-6-基）乙基]苯甲酰基]-Nδ-半邻苯二甲酰基-L-鸟氨酸的细节（2）和N（ α）-[4- [5-（2,4-二氨基萜啶-6-基）戊-1-yn-4-基]苯甲酰基]-Nδ-半邻苯二甲酰基-L-鸟氨酸（6）作为N的类似物α-（4-氨基-4-脱氧蝶酰基）-Nδ-半邻苯二甲酰基-L-鸟氨酸（1，PT523），一种不可聚谷氨酸的抗叶酸药物，目前正处于临床前发展阶段。在针对CCRF-CEM人白血病淋巴母细胞培养物的72小时生长抑制分析中，与先前报道的值4.4相比，2和6的IC（50）分别为0.69 +/- 0.044 nM和1.3 +/- 0.35 nM。氨基蝶呤（AMT）的+/- +/- 0.10 nM和PT523的1.5 +/- 0.39 nM。在使用二氢叶酸和NADPH作为共底物的分光光度法测定二氢叶酸还原酶（DHFR）抑制作用的情况下，与先前报道的3
• Analogues of the Potent Nonpolyglutamatable Antifolate <i>N</i>^α-(4-Amino-4-deoxypteroyl)-<i>N</i>^δ-hemiphthaloyl-<scp>l</scp>-ornithine (PT523) with Modifications in the Side Chain, <i>p</i>-Aminobenzoyl Moiety, or 9,10-Bridge:  Synthesis and in Vitro Antitumor Activity
  作者：Andre Rosowsky、Joel E. Wright、Chitra M. Vaidya、Ronald A. Forsch、Henry Bader

  DOI：10.1021/jm990630f

  日期：2000.4.1

  Seven N-alpha-(4-amino-4-deoxypteroyl)-N-sigma-hemiphtha (2, PT523) analogues were synthesized by modifications of the literature synthesis of the corresponding AMT (1) analogues and were tested as inhibitors of tumor cell growth. in growth assays against cultured CCRF-CEM human leukemic cells exposed to drug for 72 h, the IC50 values of analogues in which N-10 was replaced by CH2 and CHMe were found to be 0.55 +/- 0.07 and 0.63 +/- 0.08 nM, and thus these analogues are more potent than 1 (IC50 = 4.4 +/- 1.0 nM) or 2 (IC50 = 1.5 +/-: 0.39 nM). The 10-ethyl-10-deaza analogue of 2 (IC50 = 1.2 +/- 0.25 nM) was not statistically different from 2 but was more potent than edatrexate, the 10-ethyl-10-deaza analogue of 1, which had an IC50 of 3.3 +/- 0.36 nM. In contrast, the analogue of 2 with both an ethyl and a CO2Me group at the 10-position had an IC50 of 54 +/- 4.9 nM, showing this modification to be unfavorable. The 4-amino-1-naphthoic acid analogue of 2 had an IC50 Of 1.2 +/- 0.22 nM, indicating that replacement of the p-aminobenzoic acid (pABA) moiety does not diminish cytotoxicity. The analogues in which the (CH2)(3) Side chain was replaced by slightly longer CH2SCH2 and (CH2)(2)-SCH2 groups gave IC50 values of 4.4 +/- 1.1 and 5.0 +/- 0.56 nM and thus were somewhat less potent than the parent molecule. However the analogues in which the aromatic COOH group was at the meta and para positions of the phthaloyl ring had IC50 values of 7.5 +/- 0.47 and 55 +/- 0.07 nM, confirming the low potency we had previously observed with these compounds against other cell lines. Overall, the results in this study support the conclusion that, while the position of the phthaloyl COOH group and the length of the amino acid side chain in 2 are important determinants of cytotoxic potency, changes in the pABA region and 9,10-bridge are well-tolerated and can even increase potency.
• Synthesis and Potent Antifolate Activity and Cytotoxicity of B-Ring Deaza Analogues of the Nonpolyglutamatable Dihydrofolate Reductase Inhibitor <i>N</i>^α-(4-Amino-4-deoxypteroyl)-<i>N</i>^δ-hemiphthaloyl-<scp>l</scp>-ornithine (PT523)
  作者：Andre Rosowsky、Joel E. Wright、Chitra M. Vaidya、Henry Bader、Ronald A. Forsch、Clara E. Mota、Jorge Pardo、Cindy S. Chen、Ying-Nan Chen

  DOI：10.1021/jm980477+

  日期：1998.12.1

  Six new B-ring analogues of the nonpolyglutamatable antifolate N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine (PT523, 3) were synthesized with a view to determining the effect of modifications at the 5- and/or 8-position on dihydrofolate reductase (DHFR) binding and tumor cell growth inhibition The 5- and 8-deaza analogues were prepared from methyl 2-L-amino-5-phthalimidopentanoate and 4-amino-4-deoxy-N-10-formyl-5-deaza- and -8-deazapteroic acid, respectively. The 5,8-dideaza analogues were prepared from methyl 2-L-[(4-aminobenzoyl)-amino]-5-phthalimidopentanoate and 2,4-diaminoquinazoline-6-carbonitriles. The K-i for inhibition of human DHFR by the 5-deaza and 5-methyl-5-deaza analogues was about the same as that of 3 (0.35 pM), 11-fold lower than that of aminopterin (AMT, 1), and 15-fold lower than that of methotrexate (MTX, 2). However the K-i of the 8-deaza analogue was 27-fold lower than that of 1, and that of the 5,8-dideaza, 5-methyl-5,8-dideaza, and 5-chloro-5,8-dideaza analogues was approximately 50-fold lower. This trend was consistent with the published literature on the corresponding DHFR inhibitors with a glutamate side chain. In colony formation assays against the human head and neck squamous carcinoma cell line SCC25 after 72 h of treatment, the 5- and 8-deaza analogues were approximately as potent as 3, whereas the 5,8-dideaza analogue was 3 times more potent. 5-Methyl and 5-chloro substitution was also favorable, with the 5-methyl-5-deaza analogue being 2.5-fold more potent than the 5-deaza analogue. However the effect of 5-methyl substitution was less pronounced in the 5,8-dideaza analogues than in the 5-deaza analogues. The 5-chloro-5,8-dideaza analogue of 3 was the most active member of the series, with an IC50 = 0.33 nM versus 1.8 nM for 3 and 15 nM for MTX. The 5-methyl-5-deaza analogue of 3 was also tested at the National Cancer Institute against a panel of 50 human tumor cell lines in culture and was consistently more potent than 3, with IC50 values in the low nanomolar to subnanomolar range against most of the tumors. Leukemia and colorectal carcinoma cell lines were generally most sensitive, though good activity was also observed against CNS tumors and carcinomas of the breast and prostate. The results of this study demonstrate that B-ring analogues of 3 inhibit DHFR activity and tumor cell colony formation as well as, or better than, the parent compound. In view of the fact that 3 and its B-ring analogues cannot form polyglutamates, their high cytotoxicity relative to the corresponding B-ring analogues of AMT is noteworthy.
• ROSOWSKY, ANDRE;BADER, HENRY;FORSCH, RONALD A., PTERIDINES, 1,(1989) N, C. 91-98
  作者：ROSOWSKY, ANDRE、BADER, HENRY、FORSCH, RONALD A.

  DOI：——

  日期：——